On September 26, 2021, the website of Wuhan Qingfeng Kaimo Biomedical Technology Co., Ltd. was officially launched.

Those things that pharmaceutical intermediates R&D, production and management enterprises should know

In order to further strengthen the management and control of fentanyl substances and their precursors for pharmaceutical intermediates R&D, production and operation enterprises, and strictly prevent the occurrence of illegal and criminal activities in manufacturing, trafficking and smuggling, in accordance with relevant laws and policies, the relevant matters are hereby notified as follows:

2020 China Cancer Specialty Drug Payment Report released, foresees the development path of the integration of the medical insurance industry

With the continuous advancement of the "Healthy China 2030" strategy, the multi-level guarantee model is becoming a new trend.

The pharmaceutical industry has been improving for a long time, and the leader has gradually entered the value range

Based on the long-term growth of the pharmaceutical industry, GF Fund will deploy the second actively managed pharmaceutical theme fund on October 13th-GF Pharmaceutical and Health Hybrid.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.

The company is mainly engaged in the sales of raw materials, pharmaceutical intermediates and fine chemical products.

The company was established in July 2019. The company is mainly engaged in the sales, research and development of APIs, pharmaceutical intermediates and fine chemical products, as well as technical consulting and testing services for new compounds. At present, the company has 300 square meters of research and development and testing laboratories, and is equipped with a variety of modern experimental research equipment, to meet the small-scale research and development of various compounds, new pharmaceuticals, chemical intermediates and customized synthesis services.